erenumab（Aimovig）用于成人偏头痛的预防。 - Suppr

Suppr

超能文献

Erenumab (Aimovig) for Migraine Prophylaxis in Adults.

作者信息

Shreiber Alex M

机构信息

Idaho State University, Pocatello, ID, USA.

出版信息

Am Fam Physician. 2019 Jun 15;99(12):781-782.

PMID:31194488

Abstract

摘要

相似文献

Erenumab (Aimovig) for Migraine Prophylaxis in Adults.

Am Fam Physician. 2019 Jun 15;99(12):781-782.

Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).

Cell Rep. 2020 Feb 11;30(6):1714-1723.e6. doi: 10.1016/j.celrep.2020.01.029.

Erenumab: First Global Approval.

Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.

Ann Pharmacother. 2019 Sep;53(9):933-939. doi: 10.1177/1060028019835166. Epub 2019 Feb 27.

Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.

Headache. 2021 Apr;61(4):590-602. doi: 10.1111/head.14068. Epub 2021 Feb 16.

In brief: Erenumab (Aimovig) hypersensitivity.

Med Lett Drugs Ther. 2019 Mar 25;61(1568):48.

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine.

JAMA Intern Med. 2019 Mar 1;179(3):421-422. doi: 10.1001/jamainternmed.2018.7536.

Medications Approved for Preventing Migraine Headaches.

Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.

Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.

Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Erenumab (Aimovig) for Migraine Prophylaxis in Adults.

Am Fam Physician. 2019 Jun 15;99(12):781-782.

Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).

Cell Rep. 2020 Feb 11;30(6):1714-1723.e6. doi: 10.1016/j.celrep.2020.01.029.

Erenumab: First Global Approval.

Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.

Ann Pharmacother. 2019 Sep;53(9):933-939. doi: 10.1177/1060028019835166. Epub 2019 Feb 27.

Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.

Headache. 2021 Apr;61(4):590-602. doi: 10.1111/head.14068. Epub 2021 Feb 16.

In brief: Erenumab (Aimovig) hypersensitivity.

Med Lett Drugs Ther. 2019 Mar 25;61(1568):48.

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine.

JAMA Intern Med. 2019 Mar 1;179(3):421-422. doi: 10.1001/jamainternmed.2018.7536.

Medications Approved for Preventing Migraine Headaches.

Am J Med. 2020 Jun;133(6):664-667. doi: 10.1016/j.amjmed.2020.01.031. Epub 2020 Mar 5.

Erenumab: from scientific evidence to clinical practice-the first Italian real-life data.

Neurol Sci. 2019 May;40(Suppl 1):177-179. doi: 10.1007/s10072-019-03839-x.